$BEAM

Beam Therapeutics Inc.

Beam Therapeutics is a biotechnology company developing precision genetic medicines for serious diseases. Its platform combines base editing, gene delivery technologies and internal manufacturing capabilities. The base editors use CRISPR proteins and enzymes to make targeted changes to a single DNA base, and the company pursues both ex vivo and in vivo delivery. Its programs include risto-cel, an investigational therapy for sickle cell disease, and liver-targeting LNP candidates BEAM-302 for alpha-1 antitrypsin deficiency, BEAM-304 for phenylketonuria and BEAM-301 for glycogen storage disease type 1a. Beam also develops the ESCAPE platform and works with partners on genetic medicine programs. Beam makes money through collaborations and licenses, including payments tied to development, regulatory and commercial milestones. It also has internal manufacturing capabilities, including a 100,000 square foot cGMP facility in Research Triangle Park, North Carolina. Beam is headquartered in Cambridge, Massachusetts.

No enriched coverage for $BEAM in the last 7 days.

No SEC Form 4 filings for $BEAM in the last 30 days.

See all $BEAM insider activity →

Beam Reports Positive Pivotal Results For Gene-Edited Sickle Cell Therapy Risto-cel

Beam Therapeutics (BEAM) reported positive results from its BEACON trial for risto-cel, a gene-edited therapy for sickle cell disease. The study met primary and secondary endpoints, with 31 patients free from severe crises for 12 months. Beam plans to submit a BLA to the FDA by year-end 2026. BEAM stock is up 1.41% in pre-market trading.

Philly scientists helped shape proposed FDA guidance that could accelerate gene therapies for rare diseases

The FDA proposed new guidelines to streamline approval for personalized gene therapies, enabling testing of a platform against multiple mutations. Scientists from Penn Medicine and Children's Hospital of Philadelphia developed a treatment for rare diseases, receiving a $39M federal award. The draft guidance allows for umbrella clinical trials, potentially attracting more investment in rare disease therapies. Beam Therapeutics is planning a clinical trial for a PKU gene-editing medicine.

BEAM sentiment & insider activity

Recent BEAM coverage spans financial news, regulation and earnings.

What's driving BEAM

AlphAI scores every news story that mentions BEAM with an AI model for sentiment and relevance, and aggregates insider trades from Beam Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $BEAM

Score

Philly scientists helped shape proposed FDA guidance that could accelerate gene therapies for rare diseases

The FDA proposed new guidelines to streamline approval for personalized gene therapies, enabling testing of a platform against multiple mutations. Scientists from Penn Medicine and Children's Hospital of Philadelphia developed a treatment for rare diseases, receiving a $39M federal award. The draft guidance allows for umbrella clinical trials, potentially attracting more investment in rare disease therapies. Beam Therapeutics is planning a clinical trial for a PKU gene-editing medicine.

Jones Trading initiates Beam Therapeutics stock coverage with buy rating

Jones Trading initiated coverage on Beam Therapeutics (NASDAQ:BEAM) with a Buy rating and $35 price target. The stock trades at $27.79, with analysts' targets ranging from $26 to $80. The firm forecasts $3.2B peak sales for BEAM-302 by 2034. Beam reported Q2 2026 results, dosing the first patient in a pivotal trial for AATD. H.C. Wainwright reiterated its Buy rating with an $80 target.

$BEAMHighAI 8/10Earnings

Beam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing Portfolio

Beam Therapeutics Inc. (BEAM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Beam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing Portfolio Updated BEAM-302 Phase 1/2 Clinical Data Presented at ERS Demonstrated Durable Increases in Functional AAT and Reductions in Mutant Z-AAT; Co

Related tickers